WeVote
Log In

Bill

Bill

SF 4138

Definition for covered insulin for the insulin safety net program and manufacturer registration fee provision

2025-2026 Regular Session Introduced by Paul Utke

Minnesota bill establishes "covered insulin" definition and manufacturer registration fees to fund expanded insulin affordability safety net program for diabetic patients.

Referred to Health and Human Services
#healthandhealthdepartment #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · SF 4138

Legislative bill overview

SF 4138 modifies Minnesota's insulin safety net program by establishing a formal definition of "covered insulin" and introduces a manufacturer registration fee requirement. The bill appears designed to expand access to affordable insulin while creating a funding mechanism through manufacturer fees to support the program's operations.

Why is this important

Insulin affordability is a critical public health issue, with many Minnesotans rationing or skipping doses due to cost. This bill directly addresses insulin accessibility through program clarification and potentially expands funding—affecting tens of thousands of diabetic patients across the state and their out-of-pocket expenses.

Potential points of contention

  • Definition scope: The specific definition of "covered insulin" will determine which products qualify for assistance, potentially creating disputes between manufacturers and policymakers about what should be included
  • Manufacturer fee burden: Pharmaceutical companies may oppose registration fees as an additional cost that could be passed to consumers or reduce R&D investment
  • Program sustainability: Questions about whether manufacturer fees will adequately fund the program long-term or if state general funds will need supplementation

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.